Related references
Note: Only part of the references are listed.What does plasma CRP tell us about peripheral and central inflammation in depression?
Jennifer C. Felger et al.
MOLECULAR PSYCHIATRY (2020)
Investigating the neuroimmunogenic architecture of schizophrenia
R. Birnbaum et al.
MOLECULAR PSYCHIATRY (2018)
Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression
Alexandre K. Wang et al.
SCHIZOPHRENIA BULLETIN (2018)
Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia
Joshua Chiappelli et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia
Joshua Chiappelli et al.
NEUROPSYCHOPHARMACOLOGY (2018)
Using blood cytokine measures to define high inflammatory biotype of schizophrenia and schizoaffective disorder
Danny Boerrigter et al.
JOURNAL OF NEUROINFLAMMATION (2017)
The kynurenine pathway in schizophrenia and bipolar disorder
Sophie Erhardt et al.
NEUROPHARMACOLOGY (2017)
Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression
Chai K. Lim et al.
SCIENTIFIC REPORTS (2017)
Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume
S. G. Fillman et al.
MOLECULAR PSYCHIATRY (2016)
Tryptophan Metabolism and White Matter Integrity in Schizophrenia
Joshua Chiappelli et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Kynurenine and Tryptophan Levels in Patients With Schizophrenia and Elevated Antigliadin Immunoglobulin G Antibodies
Olaoluwa Okusaga et al.
PSYCHOSOMATIC MEDICINE (2016)
Cognitive Subtypes of Schizophrenia Characterized by Differential Brain Volumetric Reductions and Cognitive Decline
Danielle Weinberg et al.
JAMA PSYCHIATRY (2016)
Molecular Mechanisms and Timing of Cortical Immune Activation in Schizophrenia
David W. Volk et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
Progressive Reduction in Cortical Thickness as Psychosis Develops: A Multisite Longitudinal Neuroimaging Study of Youth at Elevated Clinical Risk
Tyrone D. Cannon et al.
BIOLOGICAL PSYCHIATRY (2015)
Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX-2 inhibition
Katerina Zavitsanou et al.
BRAIN BEHAVIOR AND IMMUNITY (2014)
Reduction of Brain Kynurenic Acid Improves Cognitive Function
Rouba Kozak et al.
JOURNAL OF NEUROSCIENCE (2014)
The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression
C. Lavebratt et al.
MOLECULAR PSYCHIATRY (2014)
Biological insights from 108 schizophrenia-associated genetic loci
Stephan Ripke et al.
NATURE (2014)
Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: Implications for schizophrenia
F. M. Notarangelo et al.
SCHIZOPHRENIA RESEARCH (2014)
Stress-Induced Increase in Kynurenic Acid as a Potential Biomarker for Patients With Schizophrenia and Distress Intolerance
Joshua Chiappelli et al.
JAMA PSYCHIATRY (2014)
Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder
S. G. Fillman et al.
TRANSLATIONAL PSYCHIATRY (2014)
Biomarkers in Schizophrenia: A Brief Conceptual Consideration
Cynthia S. Weickert et al.
DISEASE MARKERS (2013)
Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia
C. S. Weickert et al.
MOLECULAR PSYCHIATRY (2013)
Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia
S. G. Fillman et al.
MOLECULAR PSYCHIATRY (2013)
Anti-inflammatory treatment in schizophrenia
Norbert Mueller et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Serum testosterone levels are related to cognitive function in men with schizophrenia
L. Moore et al.
PSYCHONEUROENDOCRINOLOGY (2013)
Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
G. C. Prendergast et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Kynurenines in the mammalian brain: when physiology meets pathology
Robert Schwarcz et al.
NATURE REVIEWS NEUROSCIENCE (2012)
Interleukin-1β: A New Regulator of the Kynurenine Pathway Affecting Human Hippocampal Neurogenesis
Patricia A. Zunszain et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Klas R. Linderholm et al.
SCHIZOPHRENIA BULLETIN (2012)
Has an Angel Shown the Way? Etiological and Therapeutic Implications of the PCP/NMDA Model of Schizophrenia
Daniel C. Javitt et al.
SCHIZOPHRENIA BULLETIN (2012)
Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes
Ikwunga Wonodi et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients
A. M. Myint et al.
BRAIN BEHAVIOR AND IMMUNITY (2011)
3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia
Ruth Condray et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Korrapati V. Sathyasaikumar et al.
SCHIZOPHRENIA BULLETIN (2011)
Selection of reference gene expression in a schizophrenia brain cohort
Cynthia Shannon Weickert et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2010)
Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia
J. K. Yao et al.
MOLECULAR PSYCHIATRY (2010)
CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression
C. L. Raison et al.
MOLECULAR PSYCHIATRY (2010)
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation
S. Barry et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Mapping grey matter reductions in schizophrenia: An anatomical likelihood estimation analysis of voxel-based morphometry studies
A. Fornito et al.
SCHIZOPHRENIA RESEARCH (2009)
Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain
Paolo Guidetti et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry
Paolo Guidetti et al.
GLIA (2007)
Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum
A Rassoulpour et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Increased cortical kynurenate content in schizophrenia
R Schwarcz et al.
BIOLOGICAL PSYCHIATRY (2001)
The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression:: Physiopathological implications
C Hilmas et al.
JOURNAL OF NEUROSCIENCE (2001)
Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection
GJ Guillemin et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Presynaptic kynurenate-sensitive receptors inhibit glutamate release
R Carpenedo et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia
RE Gur et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Heme: A regulator of rat hepatic tryptophan 2,3-dioxygenase?
SY Ren et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2000)
Share Paper
